Along these lines, there were two cases of MLL1 fusions reported in prostate cancer (Chowdry et al., 2016) and so we decided to use the RNA‐seq data derived from prostate cancer patients in the TCGA database to investigate the occurrence of MLL1 fusions. Here, KMT2A is linked to prostate cancer.